Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

临床验证

  • Home
  • 临床验证
Validation of the 2025 ATA Risk Stratification System in a Cohort of Patients with Papillary Thyroid Carcinoma
Posted inDiabetes & Endocrinology news Oncology

Validation of the 2025 ATA Risk Stratification System in a Cohort of Patients with Papillary Thyroid Carcinoma

Posted by MedXY By MedXY 04/18/2026
A real-world study validates the 2025 ATA thyroid cancer risk guidelines, showing significant patient reclassification and identifying a new 'low-intermediate-risk' group needing tailored management approaches.
Read More
  • Mapping 2-Year Psychiatric and Neurologic Risks After Infections Across Body Systems and Age Groups: An Integrative Review
  • Combining Tissue Hypoperfusion Markers with Vasopressor Dose Enhances Mortality Risk Stratification in Refractory Septic Shock
  • Enhancing Decannulation Success in Neurologic Patients: The Role of Abdominal Electrical Stimulation Combined With Airway Clearance Techniques
  • Awake Intubation in Emergency Settings: Incidence, Techniques, and Outcomes from a Decade of Airway Registries
  • Predicting Opioid Use Disorder and Overdose Risk in Older Adults: Evaluating Prognostic Models
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in